Boston Scientific Reports Strong Q3 Growth, Acquires Nalu Medical

Boston Scientific, a leading medical technology company, has reported robust third-quarter results for 2025, showcasing significant growth across its business segments. The company also announced a strategic acquisition to bolster its neurostimulation portfolio.

Q3 Financial Performance

Boston Scientific's third-quarter revenue reached a milestone of $5 billion, representing a 20.3% year-over-year increase. While this growth rate shows a slight deceleration from the second quarter's 22% rise, it still demonstrates the company's strong market position and continued expansion.

Key highlights from the financial report include:

• Urology segment led growth with a 28% year-over-year increase
• Cardiology, the company's largest business, climbed 24% to $2.64 billion
• Med-surg division rose 16% to $1.72 billion

Mike Mahoney, chairman and CEO of Boston Scientific, commented on the results: "We delivered another exceptional quarter of strong performance across businesses and regions thanks to the winning spirit of our global team."

Acquisition of Nalu Medical

In a strategic move to enhance its chronic pain management portfolio, Boston Scientific announced a definitive agreement to acquire the remaining equity in Nalu Medical for $533 million. Nalu Medical, a private company specializing in miniaturized neurostimulation implants for chronic pain treatment, is projected to:

• Surpass $60 million in sales for 2025
• Generate year-over-year growth of more than 25% in 2026

This acquisition aligns with Boston Scientific's commitment to innovation and category leadership, as highlighted by Mahoney: "As we shared at our recent Investor Day meeting, we are well-positioned for differentiated growth that is fueled by our category leadership strategy, relentless focus on innovation and commitment to scaling capabilities."

Industry Outlook

The strong performance of Boston Scientific and its strategic acquisition reflect broader trends in the medical technology sector. As companies continue to invest in innovative technologies and expand their product portfolios, the industry is poised for continued growth and advancements in patient care.

With its diverse range of products and focus on high-growth areas such as neurostimulation, Boston Scientific is well-positioned to capitalize on emerging opportunities in the evolving healthcare landscape.